Loading organizations...
Paratus Investment operates as a South Korean private equity firm, specializing in identifying and cultivating high-growth companies across diverse industries. The firm employs a strategic investment approach, characterized by meticulous market analysis, scenario-driven structural investments, and conservative financial projections. This methodology aims to minimize risk while generating value beyond traditional financial returns for its portfolio companies.
Established in 2014, Paratus Investment was founded on the principle of partnering with promising enterprises to unlock their full potential. The firm’s inception arose from an insight into the necessity of a trusted partner who could provide both capital and strategic guidance. It has since cultivated a robust network of domestic investors, anchoring its operations in responsible investment practices and mutual trust.
The firm's clientele primarily consists of its diverse network of domestic limited partners, alongside the high-growth companies it strategically supports. Paratus Investment envisions a future where it continually fosters sustainable growth within its portfolio, solidifying its role as a reliable partner. The company remains committed to creating enduring value for all stakeholders across its dynamic investment ecosystem.
Paratus Investment has 2 tracked investments across 2 companies. The latest tracked deal is $23.0M Series B in Genome Insight in April 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 30, 2022 | Genome Insight | $23.0M Series B | Dunamu & Partners | Asan Foundation, Samsung, SCL Group, UK, DSC Investment, Intervest, KC, Schmidt, Signite Partners, Vntg |
| Mar 29, 2021 | Master Meditech | $7.1M Series A | — | Foresite Capital, Huons, INNOCENCE, King Mind Partners, Pharmbio, Samho Green Investment, Springcamp |